Engineered T-cell therapies are limited by progressive dysfunction under chronic tumor antigen exposure, and genetic perturbation of negative regulators has emerged as a promising strategy to sustain effector activity. We reanalyzed a genome-wide CRISPR knockout (KO) screen in primary human T cells under repetitive tumor stimulation; protein–protein interaction mapping revealed seven members of the cullin–RING ligase 5 (CRL5) complex as an enriched hit cluster. KO of any of these members [cullin-5 (CUL5), ARIH2, RNF7, UBE2F, UBE2L3, CISH, and DCUN1D3] enhanced tumor serial killing, and CUL5, the complex scaffold, emerged as the strongest target. CUL5 KO T cells exhibited sustained cytotoxicity, elevated effector cytokine production, and fewer exhaustion marker–positive cells while retaining antigen specificity and cytokine dependence. Quantitative ubiquitylation proteomics in resting and acutely and chronically stimulated T cells mapped CRL5-dependent candidate substrates beyond the canonical JAK/STAT axis, including nutrient transporters, receptor trafficking proteins, and T-cell receptor (TCR) signaling components. The benefit of CUL5 KO extended across chimeric antigen receptor (CAR) targeting CD19, B-cell maturation antigen (BCMA), and human epidermal growth factor receptor 2 (HER2) with different costimulatory domains and to 1XX-modified CAR and human leukocyte antigen–independent TCR architectures. Combining CUL5 ablation with a tumor-induced IL2 circuit produced tumor control across nine rounds of repetitive stimulation, whereas either modification alone eventually failed. In vivo, CUL5 KO BCMA CAR T cells were enriched in the bone marrow following repeated tumor rechallenge and exhibited enhanced ex vivo cytotoxicity after nearly 90 days in tumor-bearing mice. These findings position CUL5 perturbation as a strategy to improve T-cell persistence and the efficacy of adoptive cell therapies, potentially with engineered cytokine support. Significance: Knockout of CLR5 complex members, especially CUL5, attenuates T-cell exhaustion during prolonged tumor exposure, enabling CAR- and TCR-engineered T cells to sustain cytotoxicity during repeated tumor challenge. See related commentary by Hanina and Maus, p. XX . See related article by Saco et al., p. XX .